Abstract
Rationale
Administration of N-methyl-d-aspartate (NMDA) receptor antagonists produce hyperlocomotion and cognitive deficits in rodents. Activation of NMDA receptors promotes adenosine release, and adenosine agonists prevent central effects of NMDA receptor antagonists. We hypothesized that if NMDA receptor antagonists require adenosine to produce behavioral effects, mice tolerant to the adenosine receptor antagonist caffeine would have a diminished response to NMDA receptor antagonists.
Objectives
To evaluate MK-801-induced hyperlocomotion and cognitive deficits after chronic caffeine treatment in mice.
Methods
Locomotor activity was analyzed in a computerized system, spontaneous alternation was assessed in the Y-maze and long-term memory was assessed with the inhibitory avoidance task in mice.
Results
Mice chronically treated with caffeine in drinking solution (1 mg/ml for 7 days) presented normal habituation and substantial tolerance to acute caffeine (30 mg/kg, i.p.) locomotor effects. MK-801 (0.25 mg/kg, i.p.) produced pronounced hyperlocomotion in water-treated mice, but this effect was abolished in caffeine-drinking mice. Chronic caffeine treatment had no influence on either normal or MK-801-induced deficits in spontaneous alternation and inhibitory avoidance tasks.
Conclusion
Hyperlocomotion induced by MK-801 may be mediated by reduced adenosinergic activity. These results also suggest that locomotor and cognitive effects of MK-801 can be dissociated and are distinctly modulated. Finally, these findings agree with the adenosine hypofunction model of schizophrenia, since NMDA receptor antagonists are a pharmacological model for this disorder.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boye SM, Grant RJ, Clarke PB (2001) Disruption of dopaminergic neurotransmission in nucleus accumbens core inhibits the locomotor stimulant effects of nicotine and d-amphetamine in rats. Neuropharmacology 40:792–805
Browne RG, Welch WM (1982) Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists. Science 217:1157–1159
Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:221–226
Castellano C, Cestari V, Ciamei A (2001) NMDA receptors and learning and memory processes. Curr Drug Targets 2:273–283
Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology 120:67–74
Craig CG, White TD (1993) N-methyl-d-aspartate- and non-N-methyl-d-aspartate-evoked adenosine release from rat cortical slices: distinct purinergic sources and mechanisms of release. J Neurochem 60:1073–1080
Cunha RA (2001) Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem Int 38:107–125
Delaney SM, Geiger JD (1998) Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-d-aspartate-induced levels by inhibitors of adenosine transport and metabolism. J Pharmacol Exp Ther 285:568–572
Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C (2002) Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 7:32–43
Finn IB, Holtzman SG (1987) Pharmacologic specificity of tolerance to caffeine-induced stimulation of locomotor activity. Psychopharmacology 93:428–434
Fraser CM, Fisher A, Cooke MJ, Thompson ID, Stone TW (1997) Purine modulation of dizocilpine effects on spontaneous alternation. Psychopharmacology 130:334–342
Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83–133
Ghisolfi E, Prokopiuk AS, Becker J, Ehelers JA, Abreu PB, Souza DO, Lara DR (2002) The adenosine antagonist theophylline impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacology 27:629–637
Gimenez-Llort L, Martinez E, Ferre S (1995) Dopamine-independent and adenosine-dependent mechanisms involved in the effects of N-methyl-d-aspartate on motor activity in mice. Eur J Pharmacol 275:171–177
Harvey J, Lacey MG (1997) A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J Neurosci 17:5271–5280
Hillion JA, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, Canela EI, Zoli M, Agnati LF, Ibanez CF, Lluis C, Franco R, Ferre S, Fuxe K (2002) Coaggregation, cointernalization and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277:18091–18097
Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 89:1–10
Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB Jr, Vegso S, Heninger GR, Charney DS (1999) Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 145:193–204
Kuribara H, Asami T, Ida I, Tadokoro S (1992) Characteristics of the ambulation-increasing effect of the noncompetitive NMDA antagonist MK-801 in mice: assessment by the coadministration with central-acting drugs. Jpn J Pharmacol 58:11–18
Lalonde R (2002) The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 26:91–104
Lara DR, Souza DO (2000) Schizophrenia: a purinergic hypothesis. Med Hypotheses 54:157–166
Lara DR, Souza DO (2001) Modelo de hipofunção adenosinérgica para a esquizofrenia: interação entre os sistemas purinérgico, glutamatérgico e dopaminérgico. Rev Psiq Clin 28:160–169
Manzoni OJ, Manabe T, Nicoll RA (1994) Release of adenosine by activation of NMDA receptors in the hippocampus. Science 265:2098–2101
Maurice T, Lockhart BP, Privat A (1996) Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706:181–193
Melani A, Corsi C, Gimenez-Llort L, Martinez E, Ogren SO, Pedata F, Ferre S (1999) Effect of N-methyl-d-aspartate on motor activity and in vivo adenosine striatal outflow in the rat. Eur J Pharmacol 385:15–19
Meredith GE, Ypma P, Zahm DS (1995) Effects of dopamine depletion on the morphology of medium spiny neurons in the shell and core of the rat nucleus accumbens. J Neurosci 15:3808–3820
Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349–1352
Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921–2927
Narayanan S, Willins D, Dalia A, Wallace L, Uretsky N (1996) Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol Biochem Behav 54:565–573
Nelson CL, Burk JA, Bruno JP, Sarter M (2002) Effects of acute and repeated systemic administration of ketamine on prefrontal acetylcholine release and sustained attention performance in rats. Psychopharmacology 161:168–179
O'Neill MF, Shaw G (1999) Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology 145:237–250
Popoli P, Reggio R, Pezzola A (1997) Adenosine A1 and A2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats. Eur J Pharmacol 333:143–146
Powell KR, Holtzmann SG (1998) Lack of NMDA receptor involvement in caffeine-induced locomotor stimulation and tolerance in rats. Pharmacol Biochem Behav 59:433–438
Qiao H, Noda Y, Kamei H, Nagai T, Furukawa H, Miura H, Kayukawa Y, Ohta T, Nabeshima T (2001) Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12:11–15
Rimondini R, Ferre S, Ogren SO, Fuxe K (1997) Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17:82–91
Sills TL, Azampanah A, Fletcher PJ (1999) The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat. Eur J Pharmacol 369:325–329
Solinas M, Ferré S, You Z, Karcz-Kubicha M, Popoli P, Goldberg SR (2002) Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 22:6321–6324
Svenningsson P, Nomikos GG, Fredholm BB (1999) The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions. J Neurosci 19:4011–4022
Yamada K, Noda Y, Hasegawa T, Komori Y, Nikai T, Sugihara H, Nabeshima T (1996) The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol Exp Ther 276:460–466
Zanatta MS, Schaeffer E, Schmitz PK, Medina JH, Quevedo J, Quillfeldt JA, Izquierdo I (1996) Sequential involvement of NMDA receptor-dependent processes in hippocampus, amygdala, entorhinal cortex and parietal cortex in memory processing. Behav Pharmacol 7:341–345
Acknowledgements
This study was supported by PRONEX (Grant # 41960904–366/96), CNPq and FAPERGS.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dall'Igna, O.P., da Silva, A.L., Dietrich, M.O. et al. Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-d-aspartate receptor antagonist MK-801 in mice. Psychopharmacology 166, 258–263 (2003). https://doi.org/10.1007/s00213-002-1362-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-002-1362-1